Citations (8)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Marc Trossaërt, Aletta Falk, Laurène Gautier, Nana Kragh, Olivia Van Hinloopen & Remi Varin. (2024) An observational study of haemophilia A patients without inhibitors using the French national claims (SNDS) database. Hematology 29:1.
Read now
Read now
Articles from other publishers (7)
Rolf Ljung, Davide Matino & Amy D. Shapiro. (2024)
Recombinant factor
IX Fc
for the treatment of hemophilia B
. European Journal of Haematology 112:5, pages 678-691.
Crossref
Crossref
Tine M.H.J. Goedhart, A. Janssen, Ron A.A. Mathôt & Marjon H. Cnossen. (2023) The road to implementation of pharmacokinetic-guided dosing of factor replacement therapy in hemophilia and allied bleeding disorders. Identifying knowledge gaps by mapping barriers and facilitators. Blood Reviews 61, pages 101098.
Crossref
Crossref
Eva Funding, Gillian Lowe, Lone H. Poulsen, Susan Shapiro, Johannes Oldenburg, Daniel Eriksson, Aletta Falk & Carly Rich. (2023) Real-World Effectiveness of rFIXFc Prophylaxis in Patients with Haemophilia B Switched from Standard Half-Life Therapy in Three European Countries. Advances in Therapy 40:9, pages 3770-3783.
Crossref
Crossref
María-Teresa Álvarez-Román, Amy D. Shapiro, Margaret V. Ragni, Helena Palmborg, Linda Bystrická, Johan Szamosi, Sandra Casiano & Hervé Chambost. (2023) Long-term outcomes of prophylaxis with a recombinant factor VIII Fc or recombinant factor IX Fc in patients with hemophilia previously treated on demand. Research and Practice in Thrombosis and Haemostasis 7:6, pages 102163.
Crossref
Crossref
Jan Blatný, Emma Munk Nielsen, Signe Baattrup Reitzel, Annabell Cajus McMillan, Anne Danø, Linda Bystrická, Nana Kragh & Robert Klamroth. (2023) Real‐world evidence on efmoroctocog alfa in patients with haemophilia A: A systematic literature review of treatment experience in Europe. Haemophilia 29:4, pages 963-974.
Crossref
Crossref
Meryl Brod, Donald M. Bushnell, Jesper Skov Neergaard, Laura Tesler Waldman & Anne Kirstine Busk. (2023) Understanding treatment burden in hemophilia: development and validation of the Hemophilia Treatment Experience Measure (Hemo-TEM). Journal of Patient-Reported Outcomes 7:1.
Crossref
Crossref
Lesley D’AlbiniMary DorholtLydia Gallucci. (2023) Optimizing maintenance dosing of emicizumab-kxwh as prophylaxis in hemophilia A: Dosing to product labeling while minimizing drug waste. Journal of Managed Care & Specialty Pharmacy 29:1, pages 47-57.
Crossref
Crossref